Program for Appropriate Technology in Health:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Program for Appropriate Technology in Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7573
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Program for Appropriate Technology in Health (PATH) is a non-profit organization that improves health in women and children. The organization offers vaccines, drugs, diagnostics, devices, system and service innovations, and digital health solutions. It develops diagnostics for HIV and other sexually transmitted infections, malaria, tuberculosis, epidemic and emerging diseases, women’s cancers, non communicable diseases, diabetes and neglected tropical diseases. PATH caters to governments, donors, and multilateral organizations. PATH collaborates with innovators, public and private-sector partners, governments, communities, and civil society groups to develop and introduce health solutions. The organization has operations in Belgium, Cambodia, China, Congo, Ethiopia, France, Ghana, India, Kenya, the US, and others. PATH is headquartered in Seattle, Washington, the US.

Program for Appropriate Technology in Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 11
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 13
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 14
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 15
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 16
Liquidia Technologies Extends Co-Development Agreement With PATH 17
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 18
Novavax Amends Co-Development Agreement With PATH 19
Program for Appropriate Technology in Health – Key Competitors 21
Program for Appropriate Technology in Health – Key Employees 22
Program for Appropriate Technology in Health – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Key Facts 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 11
Radboudumc and iMM Lisboa Enters Into Partnership with PATH 12
CMC Biologics Enters into Agreement with Path Malaria Vaccine Initiative 13
Affinivax Enters into Development Agreement with PATH for Pneumococcal Disease 14
Mymetics Enters into Co-Development Agreement with Path Malaria Vaccine Initiative 15
Scandinavian Biopharma, PATH and University of Gothenburg Amend Agreement to Develop ETEC 16
Liquidia Technologies Extends Co-Development Agreement With PATH 17
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 18
Novavax Amends Co-Development Agreement With PATH 19
Program for Appropriate Technology in Health, Key Competitors 21
Program for Appropriate Technology in Health, Key Employees 22
Program for Appropriate Technology in Health, Other Locations 23
Program for Appropriate Technology in Health, Subsidiaries 24
Program for Appropriate Technology in Health, Joint Venture 24

List of Figures
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Program for Appropriate Technology in Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Program for Appropriate Technology in Health, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Program for Appropriate Technology in Health:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sophiris Bio Inc (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostati …
  • Saneca Pharmaceuticals as:製薬・医療:M&Aディール及び事業提携情報
    Summary Saneca Pharmaceuticals as (Saneca Pharma) is a contract development and manufacturing organization that develops and manufactures active pharmaceutical ingredients and finished dosage forms. The organization provides products such as API's; 2-aminotridecane adipate, atorvastatin calcium crys …
  • Grill Concepts, Inc.:企業の戦略・SWOT・財務情報
    Grill Concepts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Grill Concepts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Midsona AB (MSON B):企業の財務・戦略的SWOT分析
    Summary Midsona AB (Midsona), formerly Midelfart Sonesson AB is a healthcare products manufacturing company that provides personal care products, health foods, and hygiene products. The company’s products include superfood, sports nutrition, dietary supplements, nutritional supplements, organic food …
  • Lonestar Heart Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lonestar Heart Inc (Lonestar Heart) is a pharmaceutical company that focuses on the development of novel cardiac restorative therapies for advanced heart failure. The company offers Algisyl cardiac implantable hydrogel and MyoTec system. Its Algisyl product provides a new treatment option fo …
  • HeartWare International Inc:製品パイプライン分析
    Summary HeartWare International Inc (HeartWare), subsidiary of Medtronic Plc is a medical device company that develops and manufactures ventricular assist devices and implantable heart pumps for the treatment of advanced heart failure. The company provides HeartWare Ventricular Assist System that co …
  • Second Sight Medical Products Inc (EYES):企業の財務・戦略的SWOT分析
    Summary Second Sight Medical Products Inc (Second Sight) is a medical device company. It develops, manufactures and markets implantable visual prosthetics for blind individuals. The company offers Argus II retinal prosthesis system, a device that restores some functional vision for people suffering …
  • Geisinger Health System-製薬・医療分野:企業M&A・提携分析
    Summary Geisinger Health System (GHS) is an integrated health services organization that provides medical and surgical specialties and sub-specialties, and related health services. It offers a range of medical services for patients suffering from diseases related to cardiology, ENT, gastroenterology …
  • Flexion Therapeutics Inc (FLXN):製薬・医療:M&Aディール及び事業提携情報
    Summary Flexion Therapeutics Inc (Flexion) develops and commercializes pain therapies. The company's pipeline is focused on indications that includes osteoarthritis knee pain (repeat administration), osteoarthritis knee synovial inflammation, bilateral knee osteoarthritis pain shoulder and hip osteo …
  • Vietnam National Oil and Gas Group-エネルギー分野:企業M&A・提携分析
    Summary Vietnam National Oil and Gas Group (Petrovietnam) is an oil and gas organization that offers oil and gas exploration and development services. The organization's services include oil and natural gas exploration and production, petroleum and financial services, processing of petrochemicals, r …
  • Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design’s p …
  • Honshu Chemical Industry Co Ltd (4115):企業の財務・戦略的SWOT分析
    Honshu Chemical Industry Co Ltd (4115) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • University of California:製薬・医療:M&Aディール及び事業提携情報
    Summary University of California is a public research university system that offers educational and research services. The university’ services include research and teaching services, graduate, undergraduate and postgraduate courses, doctoral programs and courses, master’s programs, degree programs, …
  • Idexx Laboratories Inc (IDXX):企業の財務・戦略的SWOT分析
    Idexx Laboratories Inc (IDXX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Grant Thornton International Ltd:企業の戦略的SWOT分析
    Grant Thornton International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • EL Sewedy Electric Co (SWDY):企業の財務・戦略的SWOT分析
    EL Sewedy Electric Co (SWDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • FLIR Systems Inc:企業の戦略・SWOT・財務情報
    FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report Summary FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Arab Bank Plc (ARBK):企業の財務・戦略的SWOT分析
    Arab Bank Plc (ARBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Crescent Point Energy Corp (CPG):企業の財務・戦略的SWOT分析
    Crescent Point Energy Corp (CPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Nanobiotix SA (NANO):企業の製品パイプライン分析
    Summary Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent he …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆